Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Blincyto (blinatumomab)
i
Other names:
MEDI 538, MT 103, MT103, AMG-103, MEDI-538, MT-103, AMG 103, AMG103, MEDI538
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(52)
News
Trials
Company:
Amgen, Astellas, BeiGene
Drug class:
CD3 agonist, CD19 inhibitor
Related drugs:
‹
epcoritamab-bysp (11)
elranatamab-bcmm (8)
tebentafusp-tebn (7)
MGD006 (6)
BI 764532 (5)
tarlatamab-dlle (4)
SAR442257 (4)
AZD5863 (3)
CTIM-76 (3)
EX103 (3)
JNJ-5322 (3)
A-319 (2)
AMG 794 (2)
ASP2138 (2)
mosunetuzumab-axgb (2)
NVG-111 (2)
SAR446309 (2)
talquetamab-tgvs (2)
teclistamab-cqyv (2)
CC-93269 (2)
IMC-F106C (2)
IGM-2323 (2)
AMV564 (2)
CLN-978 (1)
CT-95 (1)
glofitamab-gxbm (1)
GEN1047 (1)
ISB 1342 (1)
MGD024 (1)
MK-4002 (1)
odronextamab (1)
SAR443216 (1)
GNC-035 (1)
AMG 701 (1)
REGN4018 (1)
XmAb14045 (1)
JNJ-63898081 (1)
AMG 509 (1)
A-337 (0)
ABBV-184 (0)
ABBV-383 IV (0)
ADG138 (0)
AFM11 (0)
AMG 211 (0)
AMG 305 (0)
AMG 562 (0)
ASP2074 (0)
AVC-001 (0)
AZD0486 (0)
BA1202 (0)
BC3448 (0)
BI 765049 (0)
BNT142 (0)
BS006 (0)
CBA-1535 (0)
CC-1 (0)
CC-3 (0)
CCW702 (0)
CD30 biAb-AATC (0)
CLN-049 (0)
CM350 (0)
CM355 (0)
CMG1A46 (0)
ERY974 (0)
TRBS07 (0)
F182112 (0)
GB261 (0)
GEM333 (0)
GEN1044 (0)
GEN3017 (0)
GNC-039 (0)
GNR-084 (0)
HBM7004 (0)
HPN536 (0)
IBI-389 (0)
IGM-2537 (0)
IGM-2644 (0)
IO-312 (0)
ISB 1302 (0)
ISB 2001 (0)
JNJ-6358 (0)
JNJ-63709178 (0)
JNJ-67571244 (0)
JNJ-8343 (0)
JNJ-8543 (0)
JNJ-8902 (0)
JS203 (0)
LBL-033 (0)
FBTA05 (0)
M701 (0)
M802 (0)
MBS314 (0)
MK-6070 (0)
MP0533 (0)
NG-641 (0)
NGM936 (0)
NILK-2301 (0)
NILK-2501 (0)
NM28-2746 (0)
PF-06671008 (0)
PF-07062119 (0)
PF-07260437 (0)
PIT565 (0)
QLS31904 (0)
QLS31905 (0)
QLS32015 (0)
RG6007 (0)
RG6129 (0)
RG6232 (0)
RG6286 (0)
RG6353 (0)
RG6524 (0)
RGV004 (0)
catumaxomab (0)
SAIL66 (0)
SAR440234 (0)
TAK-186 (0)
TQB2825 (0)
TQB2934 (0)
UMG2-CD3 BTCE (0)
Undisclosed HER2Bi-armed ATC (0)
WVT078 (0)
XmAb968 (0)
Y150 (0)
ZG006 (0)
AMG 160 (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
ARB202 (0)
RG6160 (0)
RG7802 (0)
AMG 330 (0)
AMG 673 (0)
GNC-038 (0)
AMG 596 (0)
RG6234 (0)
AMG 910 (0)
huCD33-BsAb (0)
REGN5458 (0)
APVO436 (0)
GD2xCD3 (0)
MGD009 (0)
AMG 420 (0)
XmAb13676 (0)
JNJ-8780 (0)
RG6194 (0)
AMG 110 (0)
MCLA-117 (0)
XmAb18087 (0)
AMG 199 (0)
REGN5459 (0)
tafasitamab-cxix (3)
FT596 (2)
YT-19 (1)
ALA-101 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CD19.t-haNK (0)
CNTY-101 (0)
Imtox19/Imtox22 (0)
ET-190 (0)
FT522 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
ONKT101 (0)
QN-019a (0)
RG6333 (0)
SNC103 (0)
TAC01-CD19 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
epcoritamab-bysp (11)
elranatamab-bcmm (8)
tebentafusp-tebn (7)
MGD006 (6)
BI 764532 (5)
tarlatamab-dlle (4)
SAR442257 (4)
AZD5863 (3)
CTIM-76 (3)
EX103 (3)
JNJ-5322 (3)
A-319 (2)
AMG 794 (2)
ASP2138 (2)
mosunetuzumab-axgb (2)
NVG-111 (2)
SAR446309 (2)
talquetamab-tgvs (2)
teclistamab-cqyv (2)
CC-93269 (2)
IMC-F106C (2)
IGM-2323 (2)
AMV564 (2)
CLN-978 (1)
CT-95 (1)
glofitamab-gxbm (1)
GEN1047 (1)
ISB 1342 (1)
MGD024 (1)
MK-4002 (1)
odronextamab (1)
SAR443216 (1)
GNC-035 (1)
AMG 701 (1)
REGN4018 (1)
XmAb14045 (1)
JNJ-63898081 (1)
AMG 509 (1)
A-337 (0)
ABBV-184 (0)
ABBV-383 IV (0)
ADG138 (0)
AFM11 (0)
AMG 211 (0)
AMG 305 (0)
AMG 562 (0)
ASP2074 (0)
AVC-001 (0)
AZD0486 (0)
BA1202 (0)
BC3448 (0)
BI 765049 (0)
BNT142 (0)
BS006 (0)
CBA-1535 (0)
CC-1 (0)
CC-3 (0)
CCW702 (0)
CD30 biAb-AATC (0)
CLN-049 (0)
CM350 (0)
CM355 (0)
CMG1A46 (0)
ERY974 (0)
TRBS07 (0)
F182112 (0)
GB261 (0)
GEM333 (0)
GEN1044 (0)
GEN3017 (0)
GNC-039 (0)
GNR-084 (0)
HBM7004 (0)
HPN536 (0)
IBI-389 (0)
IGM-2537 (0)
IGM-2644 (0)
IO-312 (0)
ISB 1302 (0)
ISB 2001 (0)
JNJ-6358 (0)
JNJ-63709178 (0)
JNJ-67571244 (0)
JNJ-8343 (0)
JNJ-8543 (0)
JNJ-8902 (0)
JS203 (0)
LBL-033 (0)
FBTA05 (0)
M701 (0)
M802 (0)
MBS314 (0)
MK-6070 (0)
MP0533 (0)
NG-641 (0)
NGM936 (0)
NILK-2301 (0)
NILK-2501 (0)
NM28-2746 (0)
PF-06671008 (0)
PF-07062119 (0)
PF-07260437 (0)
PIT565 (0)
QLS31904 (0)
QLS31905 (0)
QLS32015 (0)
RG6007 (0)
RG6129 (0)
RG6232 (0)
RG6286 (0)
RG6353 (0)
RG6524 (0)
RGV004 (0)
catumaxomab (0)
SAIL66 (0)
SAR440234 (0)
TAK-186 (0)
TQB2825 (0)
TQB2934 (0)
UMG2-CD3 BTCE (0)
Undisclosed HER2Bi-armed ATC (0)
WVT078 (0)
XmAb968 (0)
Y150 (0)
ZG006 (0)
AMG 160 (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
ARB202 (0)
RG6160 (0)
RG7802 (0)
AMG 330 (0)
AMG 673 (0)
GNC-038 (0)
AMG 596 (0)
RG6234 (0)
AMG 910 (0)
huCD33-BsAb (0)
REGN5458 (0)
APVO436 (0)
GD2xCD3 (0)
MGD009 (0)
AMG 420 (0)
XmAb13676 (0)
JNJ-8780 (0)
RG6194 (0)
AMG 110 (0)
MCLA-117 (0)
XmAb18087 (0)
AMG 199 (0)
REGN5459 (0)
tafasitamab-cxix (3)
FT596 (2)
YT-19 (1)
ALA-101 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CD19.t-haNK (0)
CNTY-101 (0)
Imtox19/Imtox22 (0)
ET-190 (0)
FT522 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
ONKT101 (0)
QN-019a (0)
RG6333 (0)
SNC103 (0)
TAC01-CD19 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
›
Associations
(52)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
CD19 positive
Acute Lymphocytic Leukemia
CD19 positive
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
CD19 positive
B Acute Lymphoblastic Leukemia
CD19 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A2 - Guideline
blinatumomab
Sensitive
:
A2
blinatumomab
Sensitive: A2 - Guideline
blinatumomab
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
CD20 positive
B Acute Lymphoblastic Leukemia
CD20 positive
B Acute Lymphoblastic Leukemia
rituximab + blinatumomab
Sensitive: A2 - Guideline
rituximab + blinatumomab
Sensitive
:
A2
rituximab + blinatumomab
Sensitive: A2 - Guideline
rituximab + blinatumomab
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: C2 – Inclusion Criteria
blinatumomab
Sensitive
:
C2
blinatumomab
Sensitive: C2 – Inclusion Criteria
blinatumomab
Sensitive
:
C2
CD22 positive
B Acute Lymphoblastic Leukemia
CD22 positive
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
blinatumomab + inotuzumab ozogamicin
Sensitive
:
C2
blinatumomab + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
blinatumomab + inotuzumab ozogamicin
Sensitive
:
C2
CD22 expression
B Acute Lymphoblastic Leukemia
CD22 expression
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
blinatumomab + inotuzumab ozogamicin
Sensitive
:
C2
blinatumomab + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
blinatumomab + inotuzumab ozogamicin
Sensitive
:
C2
BCR-ABL1 E255K
Acute Lymphocytic Leukemia
BCR-ABL1 E255K
Acute Lymphocytic Leukemia
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
dasatinib + blinatumomab
Sensitive
:
C3
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
dasatinib + blinatumomab
Sensitive
:
C3
BCR-ABL1 D276G
Acute Lymphocytic Leukemia
BCR-ABL1 D276G
Acute Lymphocytic Leukemia
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
dasatinib + blinatumomab
Sensitive
:
C3
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
dasatinib + blinatumomab
Sensitive
:
C3
IL17A rs3819024
Acute Lymphocytic Leukemia
IL17A rs3819024
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
PAK4 deletion
B Acute Lymphoblastic Leukemia
PAK4 deletion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
CDKN2A deletion
B Acute Lymphoblastic Leukemia
CDKN2A deletion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
MLL rearrangement
Acute Lymphocytic Leukemia
MLL rearrangement
Acute Lymphocytic Leukemia
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Resistant
:
C3
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Resistant
:
C3
CDKN2A deletion
Acute Lymphocytic Leukemia
CDKN2A deletion
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
TP53 mutation
B Acute Lymphoblastic Leukemia
TP53 mutation
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
MLL rearrangement
B Acute Lymphoblastic Leukemia
MLL rearrangement
B Acute Lymphoblastic Leukemia
blinatumomab
Resistant: C3 – Early Trials
blinatumomab
Resistant
:
C3
blinatumomab
Resistant: C3 – Early Trials
blinatumomab
Resistant
:
C3
TP53 mutation
B Acute Lymphoblastic Leukemia
TP53 mutation
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Resistant
:
C3
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Resistant
:
C3
IKZF1 deletion
Acute Lymphocytic Leukemia
IKZF1 deletion
Acute Lymphocytic Leukemia
dasatinib + blinatumomab
Resistant: C3 – Early Trials
dasatinib + blinatumomab
Resistant
:
C3
dasatinib + blinatumomab
Resistant: C3 – Early Trials
dasatinib + blinatumomab
Resistant
:
C3
CD20 positive
B Acute Lymphoblastic Leukemia
CD20 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
PD-1 overexpression
B Acute Lymphoblastic Leukemia
PD-1 overexpression
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
IKZF1 mutation
Acute Lymphocytic Leukemia
IKZF1 mutation
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
PAX5 mutation
Acute Lymphocytic Leukemia
PAX5 mutation
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
PAK4 deletion
Acute Lymphocytic Leukemia
PAK4 deletion
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
CD19 deletion
B Acute Lymphoblastic Leukemia
CD19 deletion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
MLL translocation
B Acute Lymphoblastic Leukemia
MLL translocation
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
ponatinib + blinatumomab
Sensitive: C3 – Early Trials
ponatinib + blinatumomab
Sensitive
:
C3
ponatinib + blinatumomab
Sensitive: C3 – Early Trials
ponatinib + blinatumomab
Sensitive
:
C3
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
dasatinib + blinatumomab
Sensitive
:
C3
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
dasatinib + blinatumomab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login